A case of concomitant EGFR/ALK alteration against a mutated EGFR background in early-stage lung adenocarcinoma
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Rare cases of lung adenocarcinoma (LUAD) with concomitant epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) translocation have been reported. However, their clonal and evolutional relationship remains unclear. We report a case of early-stage EGFR-mutated LUAD with a focal concomitant EGFR/ALK alteration. A 63-year-old male underwent lobectomy to remove a 1.9-cm-sized lung nodule, which was diagnosed with EGFR-mutated LUAD. ALK immunohistochemistry (IHC) showed focal positivity within the part of the tumor characterized by lepidic pattern, also confirmed by fluorescence in-situ hybridization (FISH). Targeted next-generation sequencing was performed separately on the ALK IHC/FISH-positive and -negative areas. EGFR L833V/L858R mutations were detected in both areas, whereas EML4 (echinoderm microtubule-associated protein-like 4)-ALK translocations was confirmed only in the ALK IHC/FISH-positive area, suggesting the divergence of an EGFR/ALK co-altered subclone from the original EGFR-mutant clone. Our study suggests that concurrent alterations of EGFR and ALK can arise via divergent tumor evolution, even in the relatively early phases of tumorigenesis.
Abstract
Rare cases of lung adenocarcinoma (LUAD) with concomitant epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) translocation have been reported. However, their clonal and evolutional relationship remains unclear. We report a case of early-stage EGFR-mutated LUAD with a focal concomitant EGFR/ALK alteration. A 63-year-old male underwent lobectomy to remove a 1.9-cm-sized lung nodule, which was diagnosed with EGFR-mutated LUAD. ALK immunohistochemistry (IHC) showed focal positivity within the part of the tumor characterized by lepidic pattern, also confirmed by fluorescence in-situ hybridization (FISH). Targeted next-generation sequencing was performed separately on the ALK IHC/FISH-positive and -negative areas. EGFR L833V/L858R mutations were detected in both areas, whereas EML4 (echinoderm microtubule-associated protein-like 4)-ALK translocations was confirmed only in the ALK IHC/FISH-positive area, suggesting the divergence of an EGFR/ALK co-altered subclone from the original EGFR-mutant clone. Our study suggests that concurrent alterations of EGFR and ALK can arise via divergent tumor evolution, even in the relatively early phases of tumorigenesis.
참고문헌 (11)
- Zheng M, "Classification and pathology of lung cancer", Surg Oncol Clin N Am, 25, pp.447~468 (2016)
- Lindeman NI, "Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors : guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology", Arch Pathol Lab Med, 142, pp.321~346 (2018)
- Gainor JF, "ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS : an analysis of 1, 683 patients with non-small cell lung cancer", Clin Cancer Res, 19, pp.4273~4281 (2013)
- Won JK, "Concomitant ALK translocation and EGFR mutation in lung cancer : a comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitor", Ann Oncol, 26, pp.348~354 (2015)
- Yang JJ, "Lung cancers with concomitant EGFR mutations and ALK rearrangements : diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation", Clin Cancer Res, 20, pp.1383~1392 (2014)
- Lee JK, "Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation", Lung Cancer, 77, pp.460~463 (2012)
- Taebum Lee, "Non-small Cell Lung Cancer with Concomitant EGFR, KRAS, and ALK Mutation: Clinicopathologic Features of 12 Cases", Journal of Pathology and Translational Medicine, 50(3), pp.197~203 (2016), 대한병리학회[DOI]
- Baldi L, "Concomitant EGFR mutation and ALK rearrangement in lung adenocarcinoma is more frequent than expected : report of a case and review of the literature with demonstration of genes alteration into the same tumor cells", Lung Cancer, 86, pp.291~295 (2014)
- Schmid S, "Clinical outcome of ALK-positive non-small cell lung cancer(NSCLC)patients with de novo EGFR or KRAS co-mutations receiving tyrosine kinase inhibitors(TKIs)", J Thorac Oncol, 12, pp.681~688 (2017)
- Fan J, "Concomitant EGFR mutation and EML4-ALK rearrangement in lung adenocarcinoma is more frequent in multifocal lesions", Clin Lung Cancer, 20, pp.e517~e530 (2019)
- Hata A, "Complex mutations in the epidermal growth factor receptor gene in non-small cell lung cancer", J Thorac Oncol, 5, pp.1524~1528 (2010)